News Article | May 30, 2017
WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the first patient successfully received treatment with the Company’s lead product, INT230-6 as part of a Phase 1/2 international clinical study. Initiation of the study followed acceptance of an investigational new drug (IND) submission by the U.S. Food and Drug Administration’s Division of Oncology Products 1 (DOP1) and receipt from Health Canada of a No Objection Letter following submission of a clinical trial application (CTA). The clinical trial, IT-01 (NCT#03058289), entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers, aims to enroll approximately 60 patients with several different types of advanced solid tumors. “Bringing our novel product, INT230-6, into human testing is a major milestone for Intensity Therapeutics,” commented President and CEO Lewis H. Bender. “Over the past few years our Company has demonstrated impressive tumor shrinkage in several murine models of cancers. INT230-6 eradicated large tumors, activated a systemic immune response and improved survival. Animals having a complete response acquired the capability to spontaneous clear re-challenges of the same cancer throughout the remainder of their lives, suggesting a protective effect similar to that of a vaccine. We are therefore excited to have initiated human testing. Our staff, investigators and clinical centers are enthusiastic about bringing patients our potentially life-saving product.” This unique Phase 1/2 study will first assess the safety of INT230-6 in tumors treated at the skin surface (e.g. breast, melanoma, head-and-neck and lymphoma). Subsequent patients receiving INT230-6 will include those with deep tumors (e.g. liver, pancreatic, colon, lung and others). Investigators will utilize image guidance to inject the tumors. Additionally, a cohort is planned to explore INT230-6 in combination with anti-PD1 agents. The study’s primary goal is to demonstrate the safety of INT230-6. Secondary analyses will examine the efficacy of INT230-6 treatment via multiple parameters. The trial includes several adaptive components that will allow for adjustments in patient groups, dosing schedule and dose volumes administered. “Our studies with INT230-6 have shown the ability to stimulate a strong T-cell response as a monotherapy. There is considerably enhanced activity using INT230-6 in combination with checkpoint inhibitors such as anti-PD-1 antibodies, while maintaining a favorable safety profile,” said Chief Medical Officer Ian B. Walters, MD. “We are optimistic that our novel trial design can quickly detect evidence of direct tumor killing and immune system activation. Physicians desperately need improved treatments for patients with advanced cancers that are not responding to approved immunotherapies. Intensity Therapeutics is grateful to the volunteers participating in our study and looks forward to collecting data on INT230-6 in different cancer types.” INT230-6 is a novel, anti-cancer drug for direct intratumoral injection. The product contains potent anti-cancer agents that disperse throughout tumors and diffuse into cancer cells. INT230-6 was identified from Intensity’s DfuseRxSM platform and is being evaluated in a clinical trial; IT-01. In preclinical studies INT230-6 administration eradicated tumors by a combination of direct tumor kill coupled with recruitment of dendritic cells to the tumor micro-environment that stimulated anti-cancer T-cell activation. Treatment with INT230-6 in in vivo models of severe cancer resulted in substantial improvement in overall survival compared to standard therapies. Further, INT230-6 provided complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. IT-01 is entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers. The trial aims to enroll approximately 60 patients with different types advanced solid tumor malignancies in a multicycle dosing regimen. The study will be conducted in multiple countries and includes a cohort combining INT230-6 with an anti-PD-1 antibody. Currently the study is recruiting in the U.S. at two hospitals associated with the University of Southern California (USC) and in Canada at the University Health Network (UHN) in Toronto. The principal investigator at USC is Dr. Anthony El-Khoueiry; the principal investigator at UHN is Dr. Lillian Siu. The study’s primary objective is to assess the safety and tolerability of multiple intratumoral doses of INT230-6. Secondary assessments are to understand preliminary efficacy of INT230-6 by measuring the injected and bystander tumor responses. The study will characterize the systemic pharmacokinetic profile of multiple doses of INT230-6’s drug substances after single and then multiple intratumoral injections. Exploratory analysis will characterize patient outcome, as well as evaluate various tumor and anti-tumor immune response biomarkers that may correlate with response. Data will be used to assess the progression free and overall survival in subjects receiving INT230-6. Further information can be found at www.clinicaltrials.gov (NCT#03058289). Intensity Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer. The Company uses its DfuseRxSM platform technology to create new drug formulations that disperse throughout a tumor and diffuse into cancer cells. Drug products created using the technology are capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack distal tumors and micrometastases. Further information can be found at www.intensitytherapeutics.com. This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.
News Article | May 31, 2017
Strokes in a certain part of the brain increase alcohol-seeking behavior and preference for alcohol, according to new research with rats. Although it is known that excessive alcohol intake (more than two drinks per day) is a risk factor for stroke, there hasn’t been much scientific study about how alcohol-related behavior might change after a stroke has occurred. “It’s important because although stroke is a severe disease, more and more people are surviving and recovering after their first stroke,” says Jun Wang, assistant professor in the department of neuroscience and experimental therapeutics at the Texas A&M University College of Medicine and co-principal investigator of the project. “Therefore, it is important to study behavior change after stroke, and how that behavior can affect the chances of having another one, which is often fatal.” People who have had one stroke are often advised to limit their consumption of alcohol to help prevent a recurrence, but that may be difficult if damage caused by the stroke itself is encouraging them to actually drink more. That might help explain anecdotal reports that compliance with the instruction not to drink after a stroke is low. “In an ischemic stroke, a blood vessel to the brain is blocked, which deprives the neurons in the brain of glucose and oxygen,” says Farida Sohrabji, professor in the department of neuroscience and experimental therapeutics and co-principal investigator of the project. “Neurons are very dependent on these two nutrients, and without them, neurons very rapidly begin to die.” After an ischemic stroke in the middle cerebral artery—one of the most common types of stroke in humans—the animal models showed much lower overall fluid intake but increased preference for alcohol over water when they did drink. These effects were significant even though the stroke only affected one side of the brain, leaving the other half of the brain without damage. “Their preference for alcohol can be seen five days after stroke and through at least the first month after the stroke,” Wang says. “Specifically, when given a choice between water and alcohol, they chose alcohol a higher percentage of the time than they did before the stroke.” The researchers think that the stroke kills neurons in a part of the brain called the dorsal lateral striatum, and they stop inhibiting certain neurons in the midbrain. These midbrain neurons, which are now far more excitable, send a signal to a particular type of dopamine receptor, called D1. These D1 receptor-containing cells, located in the dorsomedial striatum, were shown in Wang’s previous work to compel the individual to perform an action—like having an alcoholic beverage. “This circuit is interesting because it means that when the dorsal lateral striatum neurons die, the result is increased excitement of the D1 neurons in the dorsomedial striatum,” Wang says. “It is this increased excitement that we think is causing alcohol-seeking behavior.” However, when the D1 receptor was inhibited, alcohol-seeking behavior in individuals with stroke damage decreased significantly while the control group didn’t exhibit much of a change. “This is a hint at how the brain works,” Wang says, “and although we’re a long way off, something to inhibit this D1 receptor might be a possible therapeutic target for a drug to help people resist the urge to drink after a stroke.” “As much as possible, we tried to use a model that would replicate the experience of a human patient,” Sohrabji says. “Therefore, we think that these findings, although preliminary, might eventually help people who have experienced any type of brain injury, whether a stroke or an accident that causes traumatic brain injury.” The findings appear in Scientific Reports. The Texas A&M University Health Science Center Division of Research supported the work. Other funding for the research came from the National Institute on Alcohol Abuse and Alcoholism and the National Institute of Neurological Disorders and Stroke.
News Article | May 30, 2017
ASPEN, Colo., May 30, 2017 /PRNewswire/ -- The Cosmetic Bootcamp® the leader in content driven core aesthetic training, is pleased to award Skylar Souyoul its annual prize. Skylar received her Bachelor of Science undergraduate degree in finance at Tulane University. She went on to receive her medical degree from Tulane University School of Medicine. After completing an internal medicine internship at Tulane Hospital she entered the dermatology program at Louisiana State University Health Science Center, serving as Chief resident in her final year. Dr Souyoul will join the Lupo Center for Aesthetic and General Dermatology in August 2017 as an associate physician. The Cosmetic Bootcamp® Summer meeting is once again sold out for its upcoming June meeting in Aspen. Future meetings for Aesthetic Providers include a Fall Meeting in Las Vegas and regional meetings throughout the country.
News Article | May 31, 2017
BERLIN & MONTREAL--(BUSINESS WIRE)--Scopis, a company specializing in surgical navigation and medical augmented and mixed reality, has announced that McGill University Health Center (MUHC) will be the first reference center and hospital in North America to use Scopis’s TGS (target-guided surgery) and augmented reality (AR) technologies in ear, nose and throat (ENT) surgeries. The MUHC, one of the world’s leading academic health centers, has a renowned reputation in ENT surgery. Dr. Marc Tewfik, Assistant Professor and Director of Rhinology at the MUHC, has performed multiple surgeries using this highly technically advanced and fully OR-integrated navigation system, with positive patient outcomes. “The ability to identify critical anatomical structures and plan safe pathways optimizes the surgical planning process,” said Dr. Tewfik. “Scopis’ TGS technology combined with augmented reality enable us to follow safe pathways during surgery and to perform procedures according to plan. This can both reduce operating time and enhance clinical outcomes.” A video highlighting the system’s advantages can be found here: https://youtu.be/WeEhQU41NuY “Surgical planning and the surgery itself can also be recorded by the system. This turns any operation into educational content that we can use to teach the next generation of surgeons,” said Professor and Chairman Dr. Nader Sadeghi. “This cutting-edge technology underlines our focus on education and using innovative solutions to solve complex medical challenges.” “Scopis is honored to have established such a strong partnership with the ENT department at McGill University Health Center,” said Bartosz Kosmecki, CEO and Founder of Scopis. Scopis is a leader in medical augmented reality (AR), mixed reality, and hybrid navigation, creating innovative solutions for the healthcare market, including technology for surgical education, and planning and navigation systems for otorhinolaryngology (ENT), craniomaxillofacial (CMF), neuro- and spine surgery, and bronchoscopy. Surgeons have performed more than 10,000 surgeries worldwide in over 50 countries with the aid of Scopis’ products and have benefitted from the highly-advanced image guidance and visualization capabilities of Scopis’ technology. Scopis recently introduced its first mixed-reality surgical holographic navigation platform integrating Microsoft HoloLens for open and minimally-invasive spine surgery. Scopis is known as one of the top vendors and innovators for surgical navigation systems and has business operations in Germany and the United States. www.scopis.com For Visual and Multimedia Representations of Scopis’ Products: *Regional availability. Not all Scopis products are available for sale in the United States.
News Article | May 31, 2017
Brain changes after stroke may lead to increase in alcohol-seeking behavior, at least in animal models, according to research published in the journal Scientific Reports. Although it is known that excessive alcohol intake (more than two drinks per day) is a risk factor for stroke, there hasn't been much scientific study about how alcohol-related behavior might change after a stroke has occurred. When researchers at the Texas A&M College of Medicine looked into the issue, they found that strokes in a certain part of the brain increase alcohol-seeking behavior and preference for alcohol. "It's important because although stroke is a severe disease, more and more people are surviving and recovering after their first stroke," said Jun Wang, MD, PhD, assistant professor in the Department of Neuroscience and Experimental Therapeutics at the College of Medicine and co-principal investigator of this project. "Therefore, it is important to study behavior change after stroke, and how that behavior can affect the chances of having another one, which is often fatal." People who have had one stroke are often advised to limit their consumption of alcohol to help prevent a recurrence, but that may be difficult if damage caused by the stroke itself is encouraging them to actually drink more. That might help explain anecdotal reports that compliance with the instruction not to drink after a stroke is low. "In an ischemic stroke, a blood vessel to the brain is blocked, which deprives the neurons in the brain of glucose and oxygen," said Farida Sohrabji, PhD, presidential impact fellow and professor in the Department of Neuroscience and Experimental Therapeutics at the College of Medicine and co-principal investigator of this project, who studies acute and long-term consequences of strokes, as well as novel stroke therapies. "Neurons are very dependent on these two nutrients, and without them, neurons very rapidly begin to die." After an ischemic stroke in the middle cerebral artery -- one of the most common types of stroke in humans -- the animal models showed much lower overall fluid intake but increased preference for alcohol over water when they did drink. These effects were significant even though the stroke only affected one side of the brain, leaving the other half of the brain without damage. "Their preference for alcohol can be seen five days after stroke and through at least the first month after the stroke," Wang said. "Specifically, when given a choice between water and alcohol, they chose alcohol a higher percentage of the time than they did before the stroke." What the researchers think is happening is that the stroke kills neurons in a part of the brain called the dorsal lateral striatum, and they stop inhibiting certain neurons in the midbrain. These midbrain neurons, which are now far more excitable, send a signal to a particular type of dopamine receptor, called D1. These D1 receptor-containing cells, located in the dorsomedial striatum, were shown in Wang's previous work to compel the individual to perform an action -- like having an alcoholic beverage. "This circuit is interesting because it means that when the dorsal lateral striatum neurons die, the result is increased excitement of the D1 neurons in the dorsomedial striatum," Wang said. "It is this increased excitement that we think is causing alcohol-seeking behavior." However, when the D1 receptor was inhibited, alcohol-seeking behavior in individuals with stroke damage decreased significantly while the control group didn't exhibit much of a change. "This is a hint at how the brain works," Wang said, "and although we're a long way off, something to inhibit this D1 receptor might be a possible therapeutic target for a drug to help people resist the urge to drink after a stroke." "As much as possible, we tried to use a model that would replicate the experience of a human patient," Sohrabji said. "Therefore, we think that these findings, although preliminary, might eventually help people who have experienced any type of brain injury, whether a stroke or an accident that causes traumatic brain injury." This study was a collaboration between the laboratories of Wang, who studies alcohol use disorders, and Sohrabji, who studies ischemic stroke, and funded by a seed grant from the Texas A&M University Health Science Center Division of Research. Other funding for the research was provided by grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute of Neurological Disorders and Stroke (NINDS).
News Article | May 31, 2017
TORONTO, ONTARIO / ACCESSWIRE / May 30, 2017, Theralase Technologies Inc. ("Theralase®" or the "Company") (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the three-month period ended March 31, 2017, total revenue increased to $507,428 from $411,448 for the same period in 2016, a 23% increase. In Canada, revenue increased 79% to $322,186 from $180,069 In the US, revenue decreased 7% to $141,714 from $152,375 and international revenue decreased 45% to $43,528 from $79,004. The increase in Canadian revenue in 2017 and the corresponding decrease in US and international revenue is attributable to the Company experiencing slower than expected sales growth of the TLC-2000 in 2016 and 1Q2017, systematically building its sales and marketing teams in the Canadian and then the US market, the learning curves associated with training and developing a new sales force in both jurisdictions and the ramp-up strategy of successfully commercializing the TLC-2000 therapeutic laser system. The Company has experienced slower than expected sales growth of the TLC-2000, has not achieved sales revenue guidance of $5 M in 2016, is not expected to achieve sales revenue guidance of $10 M in 2017 or the forward looking target of $50 million within 5 years of launch. The Company plans on optimizing the TLC-2000 technology in 2017 and 2018 to increase the revenue opportunities afforded to the technology through a “ ” by: - Redesigning the TLC-2000 software, firmware and hardware to allow the implementation of a “ ” and large scale commercial distribution, not expected to be completed until 2018. - Submit regulatory submissions to Health Canada and the FDA to expand the scope of the current clearances, beyond chronic knee pain, which if successful, is not expected to be completed until 2018. Cost of sales for the three-month period ended March 31, 2017 was $207,237 (41% of revenue) resulting in a gross margin of $300,191 or 59% of revenue, compared to a cost of sales of $131,764 (32% of revenue) in 2016, resulting in a gross margin of $279,684 or 68% of revenue. Cost of sales is represented by the following costs: raw materials, subcontracting, direct and indirect labour and the applicable share of manufacturing overhead. Cost of sales increased primarily by the retention of external engineering teams in order to optimize the TLC-2000 therapeutic laser system software and firmware to support the Company’s mandate of successfully commercializing the TLC-2000. Selling and marketing expenses for the three-month period ended March 31, 2017 were $410,979 representing 81% of sales, compared with $316,254 or 77% of sales in 2016. The increase is primarily due to increased spending in marketing and sales personnel, which should augment sales in future financial quarters, potentially aiding in future sales of the TLC-2000. Selling expenses are expected to increase in the future as the Company expands in Canada, the US and international markets. On-going investment in: sales personnel, marketing events and advertising are necessary expenses to generate and potentially increase revenues in subsequent financial quarters. Administrative expenses for the three-month period ended March 31, 2017 were $700,924 representing a 12% increase from $623,314 in 2016. Increases in administrative expenses are attributed to the following: - Insurance expenses increased 27% due to increased product liability coverage - General and administrative expenses increased by 65%, as a result of increased recruiting fees for sales personnel and regulatory licensing fees. - Administrative salaries increased by 15%, as a result of hiring clinical and educational staff. Gross research and development expenses totaled $668,723 for the three-month period ended March 31, 2017 compared to $477,588 in 2016 (40% increase). The increase in research and development expenses is primarily a result of the ongoing Phase Ib clinical trial for NMIBC, as well as investment into redesigning the TLC-2000 therapeutic laser system. Research and development expenses represented 38% of the Company’s operating expenses for the year and represent direct investment into the research and development expenses of the TLC-3000 anti-cancer technology and TLC-2000 therapeutic laser system. The net loss for the three-month period ended March 31, 2017 was $1,472,184, which included $141,381 of net non-cash expenses (i.e.: amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements). This compared to a net loss for the same period in 2016 of $1,145,739, which included $171,879 of net non-cash expenses. The PDT division represented $697,207 of this loss (57%). The increase in net loss is primarily due to increased investment in research and development of the TLC-3200 Medical Laser and TLC-3400 Dosimetry Fibre Optic Cage (“DFOC”) related to the support of a Phase Ib clinical study for NMIBC and sales, marketing and administrative personnel initiatives, related to achieving the successful commercialization of the next generation TLC-2000 therapeutic medical laser system and the successful launch of its recurring revenue model. The PDT division is focused on successfully completing a Phase Ib clinical trial for patients afflicted with NMIBC, utilizing its novel next generation light-activated, anti-cancer drug, TLD-1433. The Phase Ib clinical trial has been designed as follows: A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Guerin (“BCG”) and Who are Medically Unfit for or Refuse a Cystectomy Primary: Evaluate the safety and tolerability of PDT employing TLD-1433 and controlled uniform laser light (TLC-3200 System) in subjects with high risk, Ta/T1 or Tis NMIBC that are intolerant or refractory to BCG, and who are not candidates or refuse radical cystectomy Secondary: Evaluate the pharmacokinetics (“PK”) (movement and exit of drug within tissue) of TLD-1433 Phase Ib, open-label, single-arm, single-center study conducted in Canada. BCG intolerance or refractory disease are defined as inability to tolerate or failure to achieve a tumour-free state after at least one induction (a minimum of 5 instillations) followed by either a second induction (a minimum of 5 instillations) or at least 2 maintenance instillations. Subjects experiencing disease relapse within 12 months or less after finishing the second course of BCG therapy are also considered refractory. 2 phases: In the first phase, 3 subjects will receive PDT (TLC-3200 System) employing 0.35 mg/cm2 (maximum recommended starting dose) TLD1433. If treatment with the maximum recommended starting dose does not raise significant safety concerns, as determined by the safety monitoring committee, an additional 6 subjects will receive PDT with 0.70 mg/cm2 (therapeutic dose) TLD1433 The TLC-3200 Medical Laser System delivers green laser light, at a wavelength of 525 nanometers (“nm”), while the Dosimetry Fibre Optic Cage (“DFOC”) technology monitors the laser light to provide a uniform distribution of the laser light energy, in the correct dosage, to the bladder wall. The Phase Ib NMIBC clinical study protocol commenced by instilling a low dose of TLD-1433 PDC into the bladders of three (3) patients with subsequent light activation using the TLC-3200 medical laser. These patients were treated on March 30, 2017, April 12, 2017 and April 18, 2017. These three (3) patients were monitored for thirty (30) days post-procedure to ascertain achievement of the primary objective of safety and tolerability and the secondary objective of pharmacokinetics. If no Significant Adverse Events (“SAEs”) or severe Adverse Events (“AEs”) are reported, then an additional six (6) patients would be enrolled at a therapeutic dose, followed by light activation and follow-up monitoring for six (6) months. On May 26, 2017, Theralase announced that the independent Data and Safety Monitoring Board (“DSMB”) unanimously decided that the primary and secondary objectives for the first part of the Phase Ib NMIBC clinical study (“Study”) have successfully been met. Princess Margaret Cancer Centre, University Health Network (“UHN”), in accordance with the DSMB’s decision, is now recommended to enroll an additional six patients for the second part of the Study, treating them at a therapeutic dose of the PDC (0.70 mg/kg) for NMIBC using its novel PDT technology. The DSMB is comprised of three highly regarded, independent uro-oncologists; specifically: Dr. Laurence Klotz of Sunnybrook Health Sciences Centre, Dr. Nathan Perlis of the University of Toronto and Dr. Alexandre Zlotta of Mount Sinai Hospital. The clinical data on the first three patients was presented by Dr. Michael Jewett, Chair of the Medical and Scientific Advisory Board (“MSAB”). The DSMB members have unanimously recommended that the first three patients enrolled and treated in the Study successfully achieved the primary and secondary endpoints of the Study and an additional six patients are now eligible to be enrolled into the Study to be treated at a therapeutic dose of the PDC and monitored for 180 days, according to the endpoint criteria. If safety and tolerability of the procedure is demonstrated in all nine (9) patients, the Phase Ib study results will support Health Canada approval and a Phase II multi-center efficacy study for NMIBC will be commenced in Canada and the United States. Theralase’s anti-cancer technology pipeline includes numerous highly effective drug candidates, in various advanced stages of preclinical development. Theralase will continue to validate its extensive data with additional cancer animal models and toxicology analyses to bring these PDC drug candidates online for various cancer and bacterial applications. Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain and in off-label use the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle, tendon, ligament, joint and wound conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them. Additional information is available at www.theralase.com and www.sedar.com . This news release contains "forward-looking statements" which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as "may", "would", "could", “should”, "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. For More Information: Roger Dumoulin-White President & CEO 1.866.THE.LASE (843-5273) ext. 225 416.699.LASE (5273) ext. 225 [email protected] www.theralase.com Source: Theralase Technologies Inc.
News Article | June 2, 2017
CHICAGO--(BUSINESS WIRE)--Viviphi Ltd (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announced today that the PrecisionPlan™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration in precision medicine between the two organizations. PrecisionPlan™ is a cognitive computing platform that generates comprehensive, actionable and patient-specific treatment plans in a matter of seconds. The artificial intelligence solution combines patient-specific diagnostic, surgical and demographic data from the electronic medical record (EMR) with genomic and tumor sequencing information to generate personalized treatment plans that comply with nationally respected evidence and the latest clinical guidance in precision medicine. The strategic collaboration was formed in 2016 and has combined Avera’s clinical rules in genomic-based precision medicine and Viviphi’s state-of-the-art cognitive computing platform in oncology. Fred Ashbury, PhD, Chief Scientific Officer of Viviphi, noted that genomic science has opened up a whole new way to think about treating cancers, using targeted therapies and immunotherapies designed to attack the actual drivers of cancer. “These innovative therapies are now significantly improving the odds of survival for many cancer patients who were otherwise compelled to receive multiple lines of treatment using standard of care with substantially greater cost, decreasing chances of success with each line of therapy, increased side effects and poorer quality of life.” Avera is one of a handful of world leaders generating evidence-based knowledge through their practical application of genomic-based precision medicine for cancer patients. Avera will be the first health system in the world to action patient data through the Viviphi PrecisionPlan™ platform. Implementation and training will occur late in 2017. The platform was validated in clinic and through the Avera Molecular Tumor Board in February through April of this year. Other leading NCI Cancer Centers in the USA are now contracting with Viviphi and preparing for implementation in their oncology networks. Current standards of care follow a one-size-fits-all or population health approach to treatment. Existing chemotherapies do not focus on the specific drivers of the individual’s cancer and while they can destroy cancer cells, they can destroy healthy cells too, leading to a lengthier and more expensive recovery. Standard treatments for cancer are not personalized to the patient’s individual circumstances. Precision oncology offers personalized cancer therapies to patients, based on their individual genomic profile. It has been demonstrated that oncology practices that embrace both the best of genomic science and existing nationally-accepted standards of care achieve better outcomes for their patients. The absence, however, of codified clinical rules in precision medicine in oncology has left many clinicians without practical support and access to the latest knowledge and experts in this dynamic and rapidly evolving field of practice. These new diagnostic and treatment interventions come at a considerable cost, and health insurers, hospital leaders, and government payers are requiring that local practicing clinicians demonstrate competence in molecular oncology before ordering expensive next-generation tumor sequencing tests and prescribing many of the new and highly effective targeted therapies, combination treatments, and immunotherapies. Avera is an active member of the recognized Worldwide Innovative Networking (WIN) Consortium in personalized medicine, which is committed to rapidly translating genomic tailored discoveries into standards of care worldwide. Dr. Brian Leyland-Jones, along with his team, has established a next-generation tumor sequencing laboratory as part of the Avera Cancer Institute. Gerry Hogue, President and CEO of Viviphi, highlighted key differentiators of the platform. “PrecisionPlan™ quite literally puts a virtual peer-to-peer consult in the hands of busy oncologists. Oncologists are able to accelerate decision-making, improve clinical throughput and efficiency, make better and more appropriate decisions at the individual patient level.” The PrecisionPlan™ platform is also completely embeddable within the health institution’s EMR, further streamlining efficiencies. Dr. David Kapaska, Regional President and CEO of Avera McKennan Hospital & University Health Center, commented on the drivers of the relationship with Viviphi. “Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values. As such we feel it is our obligation to share our knowledge and success in the cancer space with physicians, care teams and patients battling this disease. This fundamental belief is what drives our commitment to our collaboration with Viviphi. It is our desire to help as many cancer patients and their families as much as possible and we feel our relationship with Viviphi will help us accomplish this.” Viviphi is a leading provider of precision medicine solutions for cancer therapy. Using gathered data from electronic medical records and lab systems combined with patient-specific genomic information, the PrecisionPlan™ cognitive computing platform generates comprehensive, actionable and patient-specific treatment plans to accelerate clinical decision making and advance cancer care. Viviphi also offers a patient app, GenomePlan™, currently available in the Apple App Store and via an online patient portal, to help cancer patients learn more about their treatment options and to help guide discussions with physicians. Viviphi is headquartered in Greenwood Village, Colorado. To learn more, visit www.viviphicare.com.
News Article | May 10, 2017
CHARLOTTE, N.C. & VIRGINIA BEACH, Va.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) is teaming up with 11 orthopedic specialty groups in North Carolina and Virginia on an orthopedic value-based care model for Humana Medicare Advantage members undergoing total hip or knee joint replacement procedures. Humana’s Total Joint Replacement Episode-Based Model is designed to improve quality, outcomes and cost across a person’s entire joint replacement episode of care. Humana will provide the orthopedic practices with robust data and analytics needed to better manage all aspects of their patients’ care from diagnosis to recovery. For the patient, this is expected to deliver a more coordinated care experience and to reduce complication rates and unnecessary readmissions after surgery. In North Carolina, Humana will work with EmergeOrtho (Blue Ridge Bone and Joint Clinic, Carolina Orthopaedic Specialists, Triangle Orthopaedic Associates and Wilmington Orthopaedic Group), Carolina Orthopaedic & Sports Medicine Center, Raleigh Orthopaedic Clinic, OrthoCarolina and Wake Forest University Health Sciences. In Virginia, Humana will work with Appalachian Orthopaedic Associates, Hampton Roads Orthopedic Center, and Jordan-Young Institute. Humana has 30 years of experience partnering with primary care physicians in value-based care arrangements. By focusing on quality and health, Humana experienced 20 percent lower costs in total in 2015 for members who were treated by doctors and other health care professionals in a value-based reimbursement model setting versus an estimation of original fee-for-service Medicare costs using the Centers for Medicare and Medicaid Services (CMS) Limited Data Set Files. Humana is now moving to apply the approach to specialties, such as orthopedics, where highly coordinated care supported by population health data has the ability to potentially improve outcomes, lower cost and deliver a better health care experience for patients. The participating North Carolina and Virginia orthopedic groups join the 12 orthopedic groups in Ohio and Tennessee who joined Humana’s orthopedic value-based care model in 2016 and the eight groups in Indiana and Kentucky that were announced by Humana last month. Humana’s model is similar to the State of Tennessee’s Innovation Model (SIM) Grant through the CMS for Medicaid beneficiaries. Through the new agreement, Humana’s population health capabilities, including patient data and analytics as well as chronic disease management and wellness programs, will complement the integrated care approach that each orthopedic group will employ with Humana members. “ Humana has made great strides when it comes to value-based care in the primary care space so it’s exciting to see where we can take value-based care when we apply it to more involved medical procedures like total joint replacement,” said Chip Howard, Humana’s Vice President of Payment Innovation. “ Humana’s approach is to provide orthopedic surgeons the tools they need to coordinate all aspects of their patients’ diagnosis, treatment, recovery and rehabilitation to in turn improve quality, lower cost and create a better experience for our members.” As of March 31, 2017, Humana has 1.8 million individual Medicare Advantage members and 160,000 commercial members who are cared for by 51,300 primary care providers, in more than 900 value-based relationships across 43 states and Puerto Rico. For more information, visit humana.com/accountable-care or www.humana.com/valuebasedcare. About Humana Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company’s strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country. More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of: More Information Humana is a Medicare Advantage HMO, PPO and PFFS plan with a Medicare contract. Enrollment in any Humana plan depends on contract renewal. This information is not a complete description of benefits. Contact the plan for more information. Limitations, copayments and restrictions may apply. Benefits may change each year. Other providers are available in our network. Humana Inc. and its subsidiaries (“Humana”) do not discriminate on the basis of race, color, national origin, age, disability or sex. English: ATTENTION: If you do not speak English, language assistance services, free of charge, are available to you. Call 1-800-281-6918 (TTY: 711). Español (Spanish): ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-281-6918 (TTY: 711). 繁體中文 (Chinese): 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1-800-281-6918 (TTY：711).
News Article | December 12, 2016
Event co-sponsored with George Washington University Health Workforce Institute brings together leading voices on GME, health workforce, and health policy issues WASHINGTON, DC--(Marketwired - December 12, 2016) - At an event held today, entitled GME - Where Do We Go From Here?, health workforce thought leaders discussed possible policy developments for graduate medical education (GME) in the new political environment in addition to other challenges facing residents in training and those who administer residency programs. The event was co-sponsored by the Association of Academic Health Centers (AAHC) and George Washington University's Health Workforce Institute and held on the George Washington University campus. The event can be viewed at: http://bit.ly/2hbe6iY. The event is a capstone of nationwide discussions led by AAHC. Throughout 2015-16, the association, whose members educate the next generation of health professionals, served as a neutral convener hosting roundtable sessions in response to the release of the 2014 IOM report, Graduate Medical Education That Meets the Nation's Health Needs. "Through a series of seven round table sessions held across the US, we learned about improving the alignment between teaching hospitals who receive GME Medicare funding and medical schools who are responsible for teaching and program accreditation; issues surrounding the mental health and well-being of the residents; and the needs of rural and underserved communities, among other issues," noted Dr. Steven Wartman, AAHC president and CEO. Today's meeting underscored the importance of reviewing GME's future with a panel that included Donald Berwick, former administrator of the Centers for Medicare and Medicaid Services CMS, past president of the Institute for Healthcare Improvement, and co-chair of the IOM report; Victor Dzau, president, National Academy of Medicine; Karen Fisher, chief public policy officer, Association of American Medical Colleges; Steven Wartman, president and CEO of the Association of Academic Health Centers; Gail Wilensky, senior fellow at project hope, and co-chair of the IOM report, and the panel moderator: Fitzhugh Mullan, co-director of the GW University Health Workforce Institute. AAHC believes that any reforms to the GME system must be considered as part of a larger national health workforce strategy. Wartman adds, "As a nation, we need to be thinking strategically about how to improve health workforce market efficiency by ensuring that major stakeholders are working together. We must transform how we educate medical students -- as well as other health professionals -- and what we train them to do." AAHC is a non-profit association dedicated to advancing health and well-being through the vigorous leadership of academic health centers.
News Article | February 17, 2017
The International Association of HealthCare Professionals is pleased to welcome Horace Mitchell, MD, FAANS, Neurological Surgeon, to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Horace Mitchell is a highly trained and qualified neurological surgeon with an extensive expertise in all facets of his work, especially complex spine-cervical and lumbar, scoliosis, cranial surgery, carpal tunnel, and ulnar nerve. Dr. Mitchell has been in practice for more than 21 years and is currently serving patients within The NeuroMedical Center Clinic in Baton Rouge, Louisiana. He is also affiliated with The Spine Hospital of Louisiana. Dr. Horace Mitchell attended Tulane University in New Orleans, where he graduated with his Medical Degree. He subsequently completed his General Surgery internship at Tulane-affiliated hospitals, before undertaking his residency training in Neurosurgery at St. Louis University Health Sciences Center. While at St. Louis University, Dr. Mitchell served as both an instructor and clinical professor in neurosurgery. Dr. Mitchell is certified by the American Board of Neurological Surgery, and has earned the coveted title of Fellow of the American Association of Neurological Surgery and the North American Spine Society. He currently serves as Department Chief for The NeuroMedical Center Clinic’s Neurosurgery Department. Dr. Mitchell keeps up to date with the latest advances and developments in his field by maintaining a membership with several professional organizations. He attributes his success to his hard work, as well as his willingness to listen and learn. Learn more about Dr. Mitchell here: http://www.theneuromedicalcenter.com/physician/horace-l-mitchell/ and be sure to read his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit http://www.findatopdoc.com